Sidana, S., Shune, L., Costa, L., Mina, R., Slowik, R., He, J., Mendes, J., Kwong, J., Gaudig, M., Lee, S., Sharma, M., Popat, R., Touzeau, C. (2025). Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop). Blood. https://doi.org/10.1182/blood-2025-5768